Clinical Trial Update: A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment [Phase 2]

View source ↗

Summary

This is a Phase 2 randomized study comparing dovitinib to sorafenib as first-line therapy for hepatocellular carcinoma. The trial completed and results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Dovitinib (dovitinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-04